A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

NCT04911998 · clinicaltrials.gov ↗

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin)
Metastatic Melanoma
BRAF V600 Mutation

Sponsor

Pierre Fabre Medicament